Survey on Atopic Dermatitis Prescription Treatments

In 2021, the research team at the National Eczema Association (NEA) conducted an online survey to learn about patient/caregiver experiences obtaining prescription treatments for their/their child’s atopic dermatitis and the impact of these experiences on their life.

The information provided in this survey will help guide NEA’s advocacy program to establish and advance policy agendas that address patients’ unmet needs and improve patients’ ability to get quality care and treatment.

Based on the survey responses, the NEA research team found that eczema patients frequently experience issues obtaining the therapies prescribed by their doctors. In addition, insurance coverage issues for atopic dermatitis treatments can be exacerbated by treatment issues for comorbid conditions.

Research publications

Key findings from this research were published in: Annals of Allergy, Asthma & Immunology; and Dermatology and Therapy. Click on the articles below to read the full journal article.

Annals of Allergy, Asthma & Immunology, “Financial and treatment access burden associated with atopic dermatitis comorbidities”

Dermatology and Therapy, “Evaluating Access to Prescription Medications in the Atopic Dermatitis Patient Population in the USA”

Learn more about this NEA study in the article below:

New Paper on Prescription Treatment Barriers for Eczema Patients